



EU Declaration of Conformity

(According to Annex IV of the Regulation (EU) 2017/746)

DIAGAST, 251 avenue Eugène Avinée, 59120 Loos, France, SRN FR-MF-000012310, declares that the in vitro medical devices to which this certificate relates are classified as **Class D** according to the rules set out in the Annex VIII of the Regulation (EU) 2017/746.

Blood grouping devices – Basic UDI: 3661562DPKBGRXXXXXXXXXX3S

CONTROL PK	REF B10350
Anti-A (PK1)	REF B10328
Anti-B (PK1)	REF B10329
Anti-A,B (PK1)	REF B10330
Anti-A (PK2)	REF B10331
Anti-B (PK2)	REF B10332
Anti-A,B (PK2)	REF B10333

They have been designed, produced and tested according to the essential health and safety requirements and are in conformity with the European standard NF EN ISO 13485 and the Regulation (UE) 2017/746 of the European parliament and of the council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU.

They comply to common specification for in vitro medical devices in respect to Commission Implementing Regulation (EU) 2022/1107 of 4 July 2022 laid down for devices intended for detection of blood group antigens in the ABO blood group system.

G-MED (notified body - n° 0459 - Paris - France) certificates n° 39430 (expiry date: March 16th, 2028) and n° 39431 (expiry date: October 18th, 2028) according to the conformity assessment procedure set out in the Annex IX of the Regulation (EU) 2017/746.

In consequence of, the CE mark has been affixed on the related devices.

The following EU declaration is issued under DIAGAST's responsibility as manufacturer.

CE0459

May 16th, 2024

Chief Executive Officer
Olivier BROLLI